-- 中東情勢の膠着状態が続く中、S&P500種株価指数とナスダック総合指数が4月末に終値で史上最高値を更新したことを受け、金曜日の取引開始前の米国株式先物はまちまちの動きとなった。 ダウ工業株30種平均先物は0.3%高、S&P500種株価指数先物は0.1%高、ナスダック総合指数先物は0.2%安となった。 木曜日、S&P500種株価指数は1%上昇し、7,209.01で取引を終え、史上初めて7,200ポイントの大台を突破した。ナスダック総合指数も0.9%上昇し、24,892.31で取引を終え、こちらも終値で史上最高値を更新した。 水曜日のAxiosの報道によると、ドナルド・トランプ米大統領はイランの最新の提案を拒否し、イラン政権が核開発計画に関する米国の懸念に対処する合意に同意するまで、イランの港湾に対する米国の海上封鎖は継続すると述べた。 トレーダーたちは最新の決算発表に注目した。エネルギー大手のエクソンモービル(XOM)とシェブロン(CVX)はともに第1四半期の調整後利益は減少したものの、売上高は増加したと発表した。 原油価格はまちまちの動きを見せ、北海ブレント原油(期近物)は0.5%高の1バレル110.95ドル、米国産WTI原油は0.8%安の1バレル104.21ドルとなった。 ブルームバーグがまとめた予測によると、午前9時45分(米国東部時間)に発表される4月の購買担当者景気指数(PMI)最終値は54.0で、前回値と変わらない見込みだ。 午前10時(米国東部時間)に発表される4月のサプライマネジメント協会(ISM)サービス業景況指数は53.2と予測されており、前回値の52.7から上昇する見込みだ。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.